Vendor Intelligence Report: Peptides 4 Research

Published 13 Jun 2026. 20-page investigative report on who is behind Peptides 4 Research: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 20 Finnrick lab tests, Peptides 4 Research recorded 7 pass and 13 fail, a 35% overall pass rate. The record is uneven rather than uniformly hopeless: GHK-Cu is the comparatively strongest line, while CJC-1295 and Tesamorelin are the clearest avoid-or-retest products. The full report shows how ratings change when grading thresholds tighten.

Corporate records put P4R in the new-vendor category: an August 2024 domain, a September Nevada LLC, and an early archived WordPress placeholder before the peptide storefront appeared. The identity trail is less clean than buyers should want; the legal name is Peptides 4 Research LLC, while captured pages use the reversed footer "Research 4 Peptides."

The network layer is the sharper hook. Pharmatides shares infrastructure and its age gate names Peptides 4 Research LLC terms, yet a separate Nevada Pharmatides entity is managed by another person; P4R Wholesale adds a still-unresolved phone lead. P4R also leans on MDx BioAnalytical Laboratory COAs, but MDx’s own site was captured with ISO accreditation expired and pending re-accreditation, leaving COAs as incomplete assurance.

There is one relative positive: the covered scan did not find an active X/web coupon affiliate network. That does not neutralize the buyer-risk picture: no-refunds language, a BBB D+ profile, and unverified public crystallization/particulate complaints make lot-specific verification and recourse analysis central to this file.

Inside the full report:

  • Appendix A — Finnrick laboratory data, methodology-divergence charts, and trajectories for all 5 tested products
  • Corporate chronology with Nevada entity captures, manager record, address review, and BBB profile context
  • Legal-name drift exhibits showing the "Research 4 Peptides" footer discrepancy
  • Pharmatides and P4R Wholesale network analysis, including age-gate language and unresolved operator leads
  • MDx BioAnalytical Laboratory COA exhibit with accreditation-status review
  • Buyer-risk matrix covering COA reliance, product-specific retest guidance, complaints, and customer recourse

Risk assessment

  • CJC-1295 and Tesamorelin quality-failure risk — high: Finnrick testing recorded 0/4 passes for each (ratings 18.95% and 38.1%); these are the clearest avoid/verify products in the tested catalog.
  • BPC-157 and Ipamorelin batch-consistency risk — medium: Finnrick testing split 2 pass / 2 fail on each; these lines are materially less reliable than P4R’s GHK-Cu record and require lot-level verification.
  • COA-verification risk — high: P4R relies on MDx BioAnalytical COAs; MDx’s site states ISO/IEC-17025:2017 certificate expired/pending re-accreditation, and vendor COA claims conflict with Finnrick failures.
  • Physical product-integrity complaint risk — medium: Public Reddit complaints allege crystallized Glow Blend and undissolvable particulate/clogging vials; not Finnrick-verified, but serious for injectable-use buyers.
  • Corporate-transparency and brand-confusion risk — medium: P4R LLC uses “Research 4 Peptides” on its own pages and is tied to Pharmatides/p4rwholesale without clear ownership/channel disclosure.
  • Customer-recourse risk — medium: Default no-refunds policy, BBB D+ profile, and complaint reports of poor response leave limited remedy when a lot appears defective.